Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

A Prognostic Gene Signature for Metastasis-Free Survival of Triple Negative Breast Cancer Patients

Figure 7

The BPMS is prognostic for high risk patients among good prognosis patients.

Good prognosis categories examined were: (A) the 76-gene (20 BPMS+ patients out of 290 good-prognosis patients, χ2 = 12.2), (B) 28-kinase metagene (8 BPMS+ patients out of 104 high immune response patients, χ2 = 6.9), (C) GAB2 Scaffolding (23 BPMS+ patients out of 429 good prognosis patients, χ2 = 9.7), and (D) glucocorticoid receptor signature (16 BPMS+ patients out of 121 GR-/ER- patients as defined by 50% cutoff, χ2 = 10.5). Patients were stratified for MFS using the BPMS. Red indicates patient tumors that express the BPMS signature while black indicates patient tumors that do not. Survival curves were generated by Kaplan–Meier analysis, and the indicated P-values were calculated by the log-rank test.

Figure 7